ReviewAlimentary pharmacology & therapeutics2026
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.
Review in Alimentary pharmacology & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.Alimentary pharmacology & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundUlcerative colitis (UC) is a chronic immune-mediated condition of the gastrointestinal tract with highly variable treatment responses. Current therapies focus on suppressing inflammation through aminosalicylates, corticosteroids, immunomodulators, biologics, and small molecules, yet many patients experience suboptimal outcomes, including non-response, partial response, or loss of efficacy over time. This variability has prompted increasing attention to the gut microbiome as a contributing factor.
aimsThis review aimed to compile the current evidence on how the gut microbiome modulates the efficacy and pharmacokinetics of UC therapies, including mechanisms of microbial drug metabolism and host-microbe interactions that affect immune regulation.
methodsClinical and preclinical studies exploring the role of the microbiome in UC pharmacotherapy were identified through targeted PubMed and Embase searches.
resultsMicrobial communities in the gut alter UC drug exposure and action by metabolising active compounds, modifying the host immune response, and influencing local drug absorption and clearance. Differences in microbiome composition and function between individuals may explain some of the heterogeneity in drug response, durability and adverse effect profiles. Clinical studies now show that microbiome characteristics at baseline can correlate with UC treatment outcomes and may even predict therapeutic response.
conclusionsUnderstanding these microbiome-drug relationships may improve the precision of UC therapy, support the development of microbiome-guided interventions, and inform future drug development and clinical trial design. Recognising the microbiome as an active variable in treatment response reframes pharmacology in UC as not only drug- and host-dependent but also shaped by the dynamic microbial environment of the gut.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.